Phase II clinical trial KEYNOTE-427 (NCT02853344) assessed pembrolizumab (another PD-1 inhibitor) as a single therapeutic agent for ccRCC, and it appeared as tolerable as for patients with other tumor types [117]. Here, PDCD1 is linked to neoplasm.